Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Xponance Inc.

Xponance Inc. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,713 shares of the biotechnology company’s stock after purchasing an additional 571 shares during the period. Xponance Inc.’s holdings in Sarepta Therapeutics were worth $2,275,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. CIBC Asset Management Inc boosted its stake in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 86 shares in the last quarter. Commerce Bank lifted its holdings in shares of Sarepta Therapeutics by 15.7% during the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 274 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Sarepta Therapeutics by 30.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company’s stock valued at $9,772,000 after purchasing an additional 18,095 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Sarepta Therapeutics by 1.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock worth $76,401,000 after purchasing an additional 6,992 shares in the last quarter. Finally, Algert Global LLC raised its holdings in Sarepta Therapeutics by 10.6% during the 3rd quarter. Algert Global LLC now owns 69,206 shares of the biotechnology company’s stock worth $8,643,000 after buying an additional 6,654 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $74.10 on Friday. The company has a market cap of $7.19 billion, a price-to-earnings ratio of 59.28 and a beta of 0.79. The business has a 50 day moving average price of $107.19 and a 200 day moving average price of $118.11. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a twelve month low of $73.05 and a twelve month high of $173.25.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Scotiabank cut their target price on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday. Royal Bank of Canada lowered their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $167.41.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.